Karyopharm Therapeutics | KPTI - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
AbbVie USD -6.66B 3.39B 2026-03
Abbott USD 52.06B 69M 2026-03
Amgen USD 9.19B 532M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
BioCryst Pharmaceuticals USD -553.84M 434.69M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Incyte USD 5.62B 455.37M 2026-03
J&J USD 81.19B 358M 2026-03
Karyopharm Therapeutics USD -292.93M 23.67M 2025-12
MacroGenics USD 21.2M 34.39M 2026-03
Merck USD 45.88B 6.73B 2026-03
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Novartis USD 38.93B 7.2B 2026-03
Novartis USD 38.93B 7.2B 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Roche Holding CHF 33.8B 758M 2025-12
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Takeda JPY 7.77T 129.5B 2026-03
Tectonic Therapeutic USD 230.42M 20.91M 2026-03
TG Therapeutics USD 583.13M 64.89M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Xencor USD 515.63M 119.95M 2026-03